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Abstract
Insomnia is a risk factor for the development of arterial hypertension, obesity, type 2 diabetes mellitus, cardiac rhythm dis-
orders, and myocardial infarction. At the same time, insomnia is one of the most frequent non-cardiac complaints in patients with 
cardiovascular diseases. 
The aim of the work was to study the presence of possible relationships between insomnia and the level of blood lipids.
Materials and methods. A cross-sectional study involving 118 patients was conducted. Criteria for inclusion in the study 
were age over 45 years, the presence of essential hypertension. All patients included the study underwent sampling of 7 ml of venous 
blood in the morning under fasting conditions. The content of total cholesterol (TCS), triglycerides (TG), high-density lipoprotein 
cholesterol (HDL CS) was determined by enzymatic method on a biochemical analyser Humalyzer 2000. The patient was inter-
viewed by a pre-trained study doctor.
Results. In the article a relationship between total cholesterol, low-density lipoprotein cholesterol and the presence of insom-
nia has been established and proved by statistical model. The overall statistical model accuracy is 89.6 % and statistical significance 
p < 0.005. Accuracy of insomnia prediction is 85.7 % by level of total cholesterol (TCS) and patient interview data. Only one model 
with best accuracy exists and it was estimated at the article.
Conclusions. Relationship between total cholesterol, low-density lipoprotein cholesterol and the presence of insomnia has 
been established and proved by statistical model. Accuracy of insomnia prediction is 85.7 % by level of total cholesterol (TCS) and 
patient interview data. 
Keywords: insomnia, hypertension, cholesterol, sleep disorders, low-density lipoprotein cholesterol.
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1. Introduction
Insomnia is a risk factor for the development of arterial hypertension, obesity, type 2 diabetes 
mellitus, cardiac rhythm disorders, and myocardial infarction [1]. At the same time, insomnia is one 
of the most frequent non-cardiac complaints in patients with cardiovascular diseases. More than 40 % 
of patients with cardiovascular diseases had some manifestations of insomnia [2]. For comparison, 
insomnia is diagnosed in no more than 10–13 % of individuals in the general population [3]. At the 
same time, studies on the relationship between insomnia and indicators of blood lipids demonstrate 
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quite contradictory results. An association has been established between the duration of sleep and HDL 
cholesterol level. Thus, according to another authors patients who sleep less than 6 hours and more 
than 8 hours, have low HDL cholesterol levels [4, 5]. It was established a link between short duration of 
sleep and low HDL cholesterol level [6]. It was demonstrated that improved sleep in patients with car-
diovascular diseases was accompanied by a decrease in LDL cholesterol from 2.29 to 1.43 mmol/l [2].
Insomnia, according to the International Classification of Disorders (Issue 3), developed by 
the International Academy of Disorders in 2014, has to include various manifestations: difficulty 
initiating sleep or difficulty maintaining continuous sleep, daytime manifestations of sleep distur-
bances (behavioural problems, concentration on sleep). An indispensable condition should be the 
presence of these manifestations, despite the fact that the patient has adequate conditions for sleep. 
All of these components of insomnia can affect cholesterol metabolism in different ways. Thus, it 
has been established that cholesterol metabolism depends on the circadian cycle [7], and according-
ly, insomnia can negatively affect blood lipid levels. In addition, insomnia is often associated with 
eating disorders, namely, late meals and nightly meals, which also negatively affects lipid metabo-
lism [6, 8]. One of the factors contributing to the development of lipid metabolism disorders is the in-
creased activity of the sympathetic nervous system, usually associated with insomnia [9]. The nega-
tive effect of excessive sympathetic activity on blood lipids was demonstrated in some works [10].
The aim of the work was to study the presence of possible relationships between insomnia 
and the level of blood lipids.
2. Materials and methods
A cross-sectional study involving 118 patients was conducted. The study was conducted 
at the Government Institution «National Institute of Therapy named by L. T. Malaya of National 
Ukrainian Academy of Medical Science» in 2018–2019. Criteria for inclusion in the study were age 
over 45 years, the presence of essential hypertension. The diagnosis of essential hypertension was 
established in accordance with the recommendations for the management of patients with arterial 
hypertension of the European Society of Cardiology/European Society of Hypertension in 2018 [11]. 
The study did not involve patients with a history of cardiovascular events (myocardial infarction, 
stroke), patients with heart failure or ejection fraction less than 45 %, with persistent arterial hyper-
tension, thyroid dysfunction, gastric ulcer and duodenal ulcer at exacerbation stage, with concom-
itant diseases that affect the quality of life, patients with degree 3 obesity, with concomitant active 
cancer diseases, with depressive states (organic depressive disorder (F 06.32), recurrent depressive 
disorder (F 33.0-3) or depressive episode of any severity (F 31.3-5, F 32.0-3), as well as mixed an-
xiety and depressive disorder (F 41.2) according to the criteria of the International Classification of 
Diseases, 10th revision (ICD-10), with insomnia as a symptom of any mental illness, with con-
comitant therapy with glucocorticosteroids, centrally acting antihypertensive drugs (moxonidine, 
reserpine), β-adrenergic blocking agents, somniferous agents, patients who confirmed consumption 
of food at night, patients with obstructive sleep apnoea syndrome.
2.1. Biochemical testing
All patients included in the study underwent sampling of 7 ml of venous blood in the morn-
ing under fasting conditions, after 9 hours without food, from the cubital vein to measure the lipid 
spectrum. The blood was centrifuged at 3000 rpm for 15 minutes. Plasma was used for further 
analysis, which was collected into a clean test tube.
The content of total cholesterol (TCS), triglycerides (TG), high-density lipoprotein choles-
terol (HDL CS) was determined by enzymatic method on a biochemical analyzer Humalyzer 2000, 
No. 18300-5397 (Germany). Very low density lipoprotein cholesterol (VLDL CS) was calculated 
as the ratio of TG to factor 5. Low density lipoprotein cholesterol (LDL cholesterol) was calculated 
using the formula by W. T. Friedewald:
VLDL CS = TCS–(HDL CS+TG/2.22),
where TG/2.22 conforms to cholesterol concentration in the composition of VLDL [7].
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Blood glucose level was measured by glucose oxidase method on a biochemical analyzer 
Humalyzer 2000, No. 18300-5397, the level of glycated hemoglobin (HbA1c) was measured by ion 
exchange method on the same analyzer.
2.2. Assessment of the presence of insomnia
The presence of insomnia was assessed using the criteria of the International Classification 
of Sleep Disorders (Issue 3), which was developed by the International Academy of Sleep Disorders 
in 2014: 1 – difficulty initiating sleep or maintaining continuous sleep; 2 – the availability of ade-
quate sleeping conditions; 3 – daytime effects of poor sleep quality. The patient was interviewed 
by a pre-trained study doctor.
2.3. Exclusion of sleep apnoea syndrome
To detect sleep apnoea syndrome, night monitoring was performed using the SOMNOcheck 
micro CARDIO cardio-respiratory complex (Germany). The device allows to register the flow of 
breath, blood saturation, heart rate and is certified for the diagnosis of sleep apnoea syndrome.
2.4. Ethical aspects
The study was approved by the Committee on Ethics and Deontology of the State Institu-
tion «L. T. Malaya Therapy National Institute of the National Academy of Medical Sciences of 
Ukraine» on 28 April 2017. All participants of the study signed an informed consent; preliminarily 
they were clearly explained the purpose and objectives of the study.
2.5. Statistical analysis
The type of data distribution was checked by the Kolmogorov-Smirnov (K-S) test. With 
normal distribution of continuous values, the data are presented as mean values (M) and standard 
deviation (SD); for quantitative values, the data are presented as the number (n) and frequency (%). 
The data that did not correspond to the normal distribution were presented as medians and 25 % 
and 75 % of quartiles. When comparing more than two groups, a one-way ANOVA test was used. 
When comparing two independent samples corresponding to the normal distribution, Student’s 
t-test was used. If the independent samples did not correspond to the normal data distribution, 
comparisons were performed using the Mann-Whitney (M-W) test. Discrepancies were considered 
statistically significant at p < 0.05.
To search and justify the relationship of the «Insomnia» variable with the measured 
values of cholesterol content (5 values) and history data (17 values), generalized linear mixed mo-
dels (GLMM) were used. This type of model provides high flexibility in the construction and study 
of new hypotheses, since relationships are sought at the level of average values of variables, their 
variances and covariances. GLMM is implemented as the corresponding procedure of the IBM 
SPSS Statistics package.
3. Results
Table 1 provides clinical characterization of the examined population.
At the time of inclusion in the study, metformin was taken by all patients with diabetes mel-
litus in both groups. Angiotensin-converting enzyme (ACE) inhibitors were taken by 22 (45.8 %) 
patients in the group without symptoms of insomnia, and by 22 (31.4 %) patients in the group with 
symptoms of insomnia (c2 = 0.038; p = 0.12). Sartans were taken by 31 (44.2 %) patients without 
symptoms of insomnia and 25 (52.1 %) patients with symptoms of insomnia (c2 = 0.69; p = 0.45), in-
dapamide – by 5 (7.1 %) and 3 (6.3 %) patients, respectively (c2 = 0.01; p = 0.92) (c2 = 0.02; p = 0.58), 
torasemide – by 11 (15.7 %) and 8 (16.7 %) patients, respectively (c2 = 0.02; p = 0.89). Patients in 
both groups received atorvastatin to monitor total cholesterol levels. The groups were comparable 
in terms of therapy.
The selection criteria for a statistically justified qualitative model are: information crite-
ria (Akaike and Bayes) and the statistical significance of the model as a whole and the model vari-
ables (in our case, p < 0.05). Thus, we tested all possible hypotheses and combinations of variables until 
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a statistically significant model and all its independent variables were found. The fixed (main) 
effects are represented by variables: cholesterols – TCS; history variables – «Difficulty initiating 
sleep»; «Difficulty maintaining continuous sleep» and «Concentration on poor sleep». They all 
had a level of statistical significance p < 0.005 (Fig. 1).
Table 1
General clinical characteristics of the examined patients with hypertension depending on the presence of 
insomnia symptoms (M ± SD)
Parameter With insomnia symptoms (n = 48) Without insomnia symptoms (n = 70) c2; р
Age, years 57.9 ± 9.8 58.2 ± 10.1 0.46
Men 11 (22.9 %) 16 (22.8 %) 0.29
Diabetes mellitus type 2 32 (66.7 %) 40 (57.1 %) 1.07; 0.59
Smoking 8 (16.7 %) 11 (15.7 %) 0.02; 0.89
Regular physical exercise 9 (18.8 %) 11 (15.7 %) 0.19; 0.66
SBP, mm Hg 138.2 ± 12.8 130.0 ± 5.3 0.12
DBP, mm Hg 88.5 ± 9.3 80.1 ± 4.3 0.32
HR per 1 min 71.8 ± 8.1 63.5 ± 11.2 0.04
BMI, kg/m2 32.9 ± 7.3 29.1 ± 0.6 0.96
Waist circumfe-
rence, cm
Men 114.2 ± 16.5 118.7 ± 9.2 0.90
Women 108.0 ± 14.1 106.7 ± 8.2 0.56
Hip circumfe-
rence, cm
Men 113.0 ± 12.2 113.3 ± 18.5 0.33
Women 120.5 ± 9.8 119.8 ± 11.4 0.31
Note: categorical parameters are given as the number of cases and the share, quantitative ones are given as M ± SD or as the median 
and the first – the third quartile; SBP – systolic blood pressure; DBP – diastolic blood pressure; HR – heart rate
Random effects: 1-factor «Behavioural Problems» and 2-factor combinations of TG and 
LDL cholesterol. Random effects all had significant positive covariances (Fig. 2). General cha-
racteristics of the model are presented in Fig. 3. We should note the high classification qualities of 
the constructed model: overall accuracy – 89.6 %; the accuracy of the «Insomnia» classification is 
91.8 % for «No insomnia signs» and 85.7 % for «Insomnia» (Fig. 4).








Fig. 2. Model (random effects)
Fig. 3. Overall characteristics of the model and information criteria
Fig. 4. Sensitivity and specificity of insomnia model
The t-test for independent groups confirms the significance of the difference in the mean 
values of total cholesterol and LDL at a level of p < 0.05. The K-S test confirms the normality of 










and the W-test confirms the normality of total cholesterol only at the level of p = 0.052 and HDL 
at the level of p = 0.09. Therefore, let us additionally perform nonparametric tests for independent 
groups (Table 2).
Table 2
Blood lipid parameters in groups of patients with and without insomnia, M ± SD 
Cholesterol
Insomnia
1 (N = 73) 2 (N = 42)
TCS (M ± SD**), mmol/l 5.17 ± 1.02 5.64 ± 1.22*
TG (M ± SD**), mmol/l 2.09 ± 1.55 1.86 ± 1.43
HDL (M ± SD**), mmol/l 1.60 ± 0.57 1.31 ± 0.29*
LDL (M ± SD**), mmol/l 2.94 ± 0.97 3.48 ± 1.23*
VLDL (M ± SD**), mmol/l 0.95 ± 0.73 0.84 ± 0.64
Glucose (M ± SD**), mmol/l 6.37 ± 2.34 6.96 ± 3.04
HbA1c (M ± SD**), % 6.34 ± 0.92 6.57 ± 0.99
*p<0.05 comparison between patients with insomnia and without insomnia
The Wald-Wolfowitz test confirms that the data are obtained from a single population. 
The K-S 2-sample test and the Mann-Witney U-test confirm the significance of the difference in 
the values of total cholesterol and HDL at the level of p < 0.05. Finally, the Kruskal-Wallis ANOVA 
and Median Test for multiple independent groups confirms the significance of the difference in the 
values of total cholesterol and HDL at the level of p = 0.01 (Table 3).
Table 3
Odds ratio, confidence interval and significance for different insomnia signs
History
Insomnia
OR (odds ratio) 95 % CI Significance
Difficulty initiating sleep 12.71 5.1–31.6 p < 0.0001
Difficulty maintaining sleep 14.21 5.0–40.6 p < 0.0001
Concentration on sleep 11.27 4.6–27.9 p < 0.0001
Behavioural problems 2.82 1.1–6.9 p < 0.05
4. Discussion
The unconditional role of night apnoea in the formation of cardiovascular risk, resistant 
hypertension, glucose metabolism disorders has been proven. That is why patients with night ap-
noea were excluded from this study.
When studying the relationship between sleep disorders and hypertension, most researchers 
have focused on sleep duration. It has been established that both short sleep, less than 6 hours, and 
sleep more than 8 hours are associated with the risk of developing hypertension, lipid metabolism 
disorders and increased BMI. The average age of study participants corresponded to 65.5 years, 
more than 60 % of subjects suffered from hypertension. It was found that the relationship between 
sleep duration and HDL cholesterol level had the form of a U-curve. So, what low HDL choles-
terol did patients with a sleep duration of less than 6 hours and more than 8 hours have. Those 
who slept less than 7 hours were found to have 31.1 % higher HDL cholesterol levels than patients 
with shorter sleep duration [4]. It has been shown that individuals who sleep less than 6 hours 
have significantly lower HDL cholesterol in a data analysis of 162,121 men and women found 
a higher risk [6]. An association between short sleep (less than 5 hours) and low-density lipoprotein 
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cholesterol and high triglycerides has been demonstrated for both men and women [12]. Another 
study, which included 2,705 patients, found no link between short sleep and HDL cholesterol [13]. 
But this study included patients with physiologically short sleep. In this case, the assessment of 
daytime drowsiness, or the use of insomnia criteria according to the International Classification 
of Sleep Disorders [14] is of particular importance.
Data on the effect of insomnia on lipid parameters are very limited [15–17]. No association 
has been established between insomnia and the development of dyslipidemia in persons not re-
ceiving sleeping pills [16]. A number of studies demonstrate the relationship between insomnia and 
the risk of high blood pressure, lower HDL cholesterol, increased waist circumference [18].
It was found that the reduction of insomnia in people with cardiovascular disease for 
12 weeks was accompanied by a decrease in LDL cholesterol from 2.29 to 1.43 mmol/l. But for the 
correction of insomnia, the expansion of physical activity was used, so it is not possible to associate 
these changes only with the correction of insomnia [2].
Study limitations. This study is not large and was conducted on a small sample of patients. 
Nevertheless, the data obtained will expand the view of scientists and doctors on the relationship 
and influence of sleep disorders and lipid metabolism.
Prospects for further research. Studying the effect of sleep disorders on metabolic pa-
rameters and lipid levels will allow the development of individualized therapies and improved 
correction of cardiovascular risk.
5. Conclusion
Thus, a relationship between total cholesterol, low-density lipoprotein cholesterol and the 
presence of insomnia has been established and proved by statistical model. The overall statistical 
model accuracy is 89.6 % and statistical significance p < 0.005. Accuracy of Insomnia prediction is 
85.7 % by level of total cholesterol (TCS) and patient interview data. This relationship is indepen-
dent and does not depend on other random parameters.
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